Alpha Tau (DRTS) Medical announced that it has secured a radioactive material license from the State of New Hampshire Bureau of Public Health Protection, Radiological Health Section, following completion of the first phase of construction of its commercial-scale manufacturing facility in Hudson, New Hampshire. “This is a very exciting operational milestone for Alpha Tau as we continue to prepare for future commercial operations,” stated Uzi Sofer, CEO of Alpha Tau. “I want to thank our dedicated operations and engineering teams who have spent countless hours ensuring that our facility is built to the highest standards, our partners at A&M Construction, and the officials from the New Hampshire Department of Health and Human Services involved in reviewing and approving our license. We also appreciate the support of New Hampshire’s Division of Economic Development and are excited to create more jobs in the state.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRTS:
- Alpha Tau Medical’s Innovative Approach in Pancreatic Cancer Treatment: A Study Update
- Alpha Tau Medical’s Pivotal Study on DaRT Treatment for Skin Cancer: A Market Perspective
- Alpha Tau Medical’s DaRT224 Study: A Potential Game-Changer in Cancer Treatment
- Alpha Tau Treats First Patient in U.S. Pancreatic Cancer Trial
- Alpha Tau treats first patient in U.S. multi-center pancreatic cancer trial
